You have read all your free articles, to continue reading subscribe to read the rest of this content.
The companies have entered into a definitive purchase agreement under which Novo Nordisk has acquired Prothena’s clinical stage antibody PRX004 and broader ATTR amyloidosis programme. PRX004 is a phase 2 ready anti-amyloid immunotherapy designed to deplete the amyloid deposits that are associatAlready a subscriber Login You have read all your…
As at 10 July 2018 Van Herk Investments B.V. holds nominally DKK 1,962,535 shares (each share carrying one vote) in Zealand Pharma A/S, corresponding to 6.38% of the total share capital and total voting rights Zealand Pharma A/S. Van Herk Investments, based in the Netherlands, has a long track-reAlready a…
The European Commission has granted an extension of the indication for Fiasp (fast-acting insulin aspart), approving it for the treatment of diabetes in adolescents and children (aged one year and above). This complements the previous indication, which covered adults only. “We are very pleasAlready a subscriber Login You have read…
After discussions with the FDA, the company has initiated the preparation for submitting a New Drug Application (NDA) for accelerated approval of melflufen for the treatment of patients with triple-class refractory multiple myeloma. A dialogue with the FDA During the spring, Oncopeptides has been Already a subscriber Login You have…
